Partner with the Leaders
Building Medtech
Apply to Present
medtech leaders
Apply to Exhibit
high-traffic area
Apply to Sponsor
most influential gathering
Trusted By The Companies Pioneering What’s Next
The Global Stage for
Live-Saving Innovation
To date, LSI has hosted nine global summits — six in Southern California, three across Europe — and has welcomed more than 10,000 global executives.
Too many events are light on real investors. That’s why we’ve built deep, lasting relationships with active VCs, PEs, and CVCs. and create an experience they show up for, year after year.
We’re continuing to push the bar by bringing bold ideas and new capital into medtech. This year, we are thrilled to have Harry Stebbings, Founder of 20VC, join us to discuss lessons from the best founders, the AI landscape, and its impact on healthcare.
Connect with industry-leading executives from emerging
companies,
venture capital and private equity firms, family
offices, investment
banks, global strategics, and more.
Jean Chaoui
Vice President of Clinical Applications and Solutions, Digital, Robotics and Enabling Technologies
Stryker
Present to a full house of investors and strategics
alongside the CEOs and Founders building
technology that is shaping the future of healthcare.
-
Innotive Diagnostics is developing a novel bacterial infection diagnostic system to revolutionise the diagnosis of urinary tract infections (UTIs). Delivering a 99% reduction in time to result at the point of care using its diagnostic system vs. gold standard laboratory methods. Innotive’s technology is based on novel single-cell analysis that could be applicable across a range of bacterial infections. Visit website.
James Mainwaring
Chief Commercial & Operating Officer
-
Every year, 4M new coronary stents are implanted to maintain the arteries’ functionality of patients who suffered a heart attack. However, 30% of these stents will fail within two years, and the sole method available to cardiologists to monitor stent malfunction is an angiogram—an invasive and ionizing procedure performed during surgery. We introduce the NIMBLE System, a first-in-class, non-invasive, non-ionizing microwave-based technology that enables cardiologists to obtain objective data about the status of coronary stents. This includes level of occlusion, potential fractures, or migrations that could endanger patients' lives. NIMBLE addresses a massive blue ocean market of $8 billion, allowing cardiologists to take control of their patients with heart failure, providing objective data through a convenient, non-invasive technology, aiming to save millions of lives. Visit website.
Oriol Iborra
CEO & Co-Founder
-
CAPS Medical (Israel) has developed a proprietary PlasmaSure technology that uses non thermal plasma to selectively target tumors through minimally invasive procedures. The PlasmaSure system uses existing minimally invasive tools and robotic systems, targeting a $100B TAM. CAPS effectively eliminates cancerous cells while preserving healthy tissue, allowing treatments to move from the operating room into a doctor's clinic. The technology is clinically tested and applicable to wide range of tumors. Visit website.
Ilan Uchitel
CEO
-
The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body’s own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing. Visit website.
Francis White
CEO
-
Njord is a medtech spin-off from Sahlgrenska University Hospital with a mission to solve unmet needs in radiology and patient handling. The first product launched is a novel patient transfer device (co-bot solution) Atle® 180 enabling improved efficiency and quality of care for acute care departments. The solution is already in use by +30 hospitals in Northern Europe. Visit website.
Jacob Ahrnstein
CEO & Co-founder
-
Relief Srl is an innovative Italian MedTech company developing a first-in-class device for the treatment of stress urinary incontinence (SUI). Visit website.
Gioia Lucarini
CEO and Co-Founder
-
Coramaze Technologies is developing an fast end effective solution for the treatment of tricuspid regurgitation. The TriPair system is deigned to be anchored atraumatically to the right atrium. The device is intended to be easily placed in a procedure taking less than twenty minutes, without the need for anesthesia or TEE. TriPair is agnostic of valve morphology and can be retrieved if necessary Visit website.
Jochen Reinöhl
CEO
-
Planatome is a patented technology platform, adapted from semiconductor manufacturing and licensed to industry leaders to create the world’s most advanced surgical cutting instruments – think semiconductor meets medical. Visit website.
Tim Tobin
CEO
-
Clairity develops AI-driven tools to enhance breast cancer screening and risk assessment. Its platform utilizes deep learning models to analyze mammographic images, aiming to improve early detection, reduce racial and ethnic biases, and personalize care plans. The technology is grounded in decades of research led by Dr. Connie Lehman at institutions such as Mass General Brigham and MIT. Clairity's approach seeks to transform mammography from a one-size-fits-all model to a precision medicine framework. Visit website.
Jeff Luber
CEO
-
Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient. Visit website.
Berk Tas
CEO
-
Twinical develops digital twin technologies to enhance surgical planning and navigation in complex soft tissue procedures. Its platform creates high-fidelity 3D virtual replicas of patient organs, enabling surgeons to assess tumor locations and surgical complexity preoperatively. In the operating room, Twinical's augmented reality framework transforms these digital twins into transparent organ models, providing real-time anatomical insights and supporting robotic integration for improved safety and precision. Visit website.
Mario Arico
CEO
-
The first osseointegrative biomimetic knee cartilage implant. Visit website.
Dimitrios Angelis
Co-Founder
-
Wellumio is a venture-backed company specializing in portable MRI solutions for acute neuroimaging applications. The company’s core enabling technology is a novel pulse-gradient free nuclear magnetic resonance sensor platform with an initial focus on acute stroke triage and diagnosis. Visit website.
Dr Shieak Tzeng
Co-founder & CEO
-
Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life. Visit website.
John Brumfield
CEO
-
SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory. Visit website.
Olivier Delporte
CEO
-
DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound. Visit website.
Nader Sadrzadeh
CEO
-
ConnCons integrates connectivity into infusion consumables to create a cloud to vessel end-to-end digital solution. The system enables safer, faster and automated therapies with a superior patient experience. First clinical applications are targeted at both center-based and home oncological therapy. Visit website.
Nora Herzog
CMO
-
INNITIUS develops a medical device that combines intravaginal hardware to measure cervical tissue consistency with shear elastic waves and machine learning algorithms. The device aims to provide diagnostics for multiple women’s health conditions related to childbirth timing, with dedicated algorithms for each specific indication Visit website.
Ruben Molina
CEO & Co-Founder
-
Multi-organ failure (MOF) is the main cause of death on ICUs. The ADVOS therapy offers the first and only integrated solution for MOF and acidosis. It includes the support of the liver, lungs, and kidneys in a single device. Patient survival is significantly improved through simultaneous organ detoxification and acid-base balance management. The brand-new blood purification technology revolutionizes detoxification and enables blood pH correction for the first time. The complexities of managing multiple organ failures in a single organism is addressed with a single device. Visit website.
Claus Jessen
Managing Director
-
BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians. Visit website.
Caitlin Morse
CEO
-
Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. Visit website.
Lara Zibners
Co-Founder & Chairman
-
BioAro is a biotechnology company specializing in genomics, artificial intelligence and blockchain technologies. The company offers whole genome sequencing, microbiome testing, and software solutions to support clinical testing offerings and improve overall efficiency of healthcare practices. Visit website.
Anmol Kapoor
CEO
-
Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.
James Lancaster
CEO
-
Locate Bio is working to solve some of the most complex degenerative and infectious diseases that affect the muscular skeletal system. Locate utilises Programmed Drug Release to re-align the bioavailability of existing drugs with the underlying biological need. This bio-optimisation step has demonstrated break through improvements in performance in preclinical testing. Locate Bio’s lead product, LDGraft, is entering human clinical studies next year, for the treatment of chronic lower back pain caused by degenerative disc disease. CognitOss Gel is in developed to overcome bacterial biofilm infections around non-viable tissue and orthopaedic implants. Visit website.
John von Benecke
CEO
-
LEM Surgical is focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications. Visit website.
Yossi Bar
CEO
-
Heteron's solution is a hand-held breath analyzer will screen and monitor for biomarkers of gastrointestinal and liver diseases. The technology is intended to replace existing diagnostic testing tools for point-of-care testing, ultimately allowing users to screen themselves and to monitor dietary and long-term medical interventions. Visit website.
Anastasia Rigas
CEO
-
Osteal Therapeutics is a musculoskeletal therapeutics company developing solutions for the treatment of orthopedic infections. The company's lead product, VT-X7, is a drug-device combination that utilizes high concentrations of vancomycin and tobramycin, in conjunction with a drug delivery system, to irrigate infected joint spaces as a result of periprosthetic joint infection in joint replacement patients. Visit website.
David Thompson
CEO
-
Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant. Visit website.
Christopher Haig
Co-Founder/Chief Executive Officer
-
EASEE is Precisis' neurostimulation device that can act in two modes - excitatory and inhibitory. The duality of the device allows its to be used for the treatment of many cerebral diseases, including epilepsy, depression, and cognitive disfunctions caused by stroke. Precisis is currently developing a close-loop system for their EASEE technology, which will allow the device to record brain activity and respond with targeted stimulation. Visit website.
Karl Stoklosa
CEO
-
Liva Healthcare are digitizing personal healthcare. The company's digital health platform provides users with personalized coaching and tailored lifestyle plans. Currently the company offers digital programs for weight management and diabetes prevention. Visit website.
Shahram Sharif
CEO
-
Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases. Visit website.
Mohamed Abou-Alam
CEO
-
Novel medical devices to enhance the reliability and safety of orthopedics procedures. Visit website.
Kambiz Behzadi
President
-
Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage. Visit website.
Upma Sharma
President & CEO
-
IQ Endoscopes develops single-use flexible endoscopes designed to address challenges associated with traditional reusable scopes. Their devices aim to reduce the risks of cross-contamination and eliminate the need for complex reprocessing. The company’s first-generation gastroscope, the Q Vision G-100, has received both FDA 510(k) clearance and UKCA approval. IQ Endoscopes is working towards expanding its product range to include additional gastrointestinal endoscopes by 2025. Visit website.
Matt Ginn
CEO
-
H2 Global is a pioneer in using molecular hydrogen in the fields of healthcare (including biotech and medtech), wellness, beauty, agriculture, and veterinary medicine. Visit website.
David Marsalek
President
-
InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.
-
Happitech has developed a CE-marked, smartphone-based method for effective remote monitoring of patients. The company's core competencies in artificial intelligence (AI) integration and photoplethysmography (PPG) enable effective and accurate measurement of heart rate and atrial fibrillation. Visit website.
Yosef Safi Harb
Founder and CEO
-
Pulnovo Medical is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves. Visit website.
Cynthia Chen
Chairwoman and President
-
Field Medical is developing a next-generation pulsed field ablation (PFA) solution for the treatment of cardiac arrhythmia. The company is building a purpose-built system that incorporates PFA, contact force sensing, electromagnetic localization, and artificial intelligence-enabled mapping capabilities to address the limitations of first-generation PFA technologies and deliver more efficacious therapy. Visit website.
Steven Mickelsen
CEO
-
GuideAI Health automates the early detection of peripheral vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts from IBM Watson Health. The platform addresses the 90% miss rate in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision. Visit website.
Raj Shah
CEO
-
EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. Visit website.
Marcin Golebicki
CEO
-
UNEEG Medical A/S develops cognitive technologies for continuous brain activity monitoring (EEG) to support medical and diagnostic applications. The company specializes in ultra long-term subcutaneous EEG monitoring with its CE-marked 24/7 EEG™ SubQ solution, designed to detect electrographic seizures in daily life. UNEEG’s technology provides objective insights into seizure burden for epilepsy management and aims to alert diabetics of severe hypoglycemia. The company employs approximately 100 people and has recently begun an international market launch. Visit website.
Martin Stenfeldt
CEO
-
ART MEDICAL’s smART+ Platform is designed to address the challenges of malnutrition and reduce the risk of ventilator-associated pneumonia, while also offering features that enhance ICU staff productivity. Clinically proven to reduce ICU stays and ventilation by 3.3 days and achieve up to 100% feeding efficiency—10 times more effective than standard protocols—smART+ features real-time reflux detection, dynamic nutritional compensation, and continuous tube positioning monitoring to enable precise, data-driven care. Visit website.
Ori Braun
CEO
-
Life Seal Vascular is developing an aneurysm sac management technology designed to reduce the incidence of Type II endoleaks following Endovascular Aneurysm Repair (EVAR). Type II endoleaks are the leading cause of reintervention after EVAR, and the Life Seal device is compatible with all EVAR systems. Currently in the pre-clinical stage, the company anticipates achieving First In Man (FIM) in Q2 of 2025. Visit website.
Matt Thompson, MD, FRCS
CEO
-
Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.
Ray Liu
CEO & Co-Founder
-
· Sequana Medical NV is a pioneer in treating diuretic-resistant fluid overload in liver disease, heart failure and cancer, through its alfapump and DSR technologies. · alfapump is the PMA approved, FDA breakthrough device for recurrent or refractory ascites due to liver cirrhosis – it is a fully implantable high tech pump that automatically pumps fluid to the bladder where it is naturally excreted. The US market is estimated at $2 billion, growing at 9% CAGR driven by obesity and alcohol. · DSR is the phase IIa drug development program with clinical proof of concept for the treatment of diuretic resistance and cardiorenal syndrome in heart failure. The US market alone is estimated at over $9 billion Visit website.
Ian Crosbie
CEO
-
Rekovar develops wearable biosensor technology aimed at improving the management of Neonatal Abstinence Syndrome (NAS). Its flagship product, NeoMonki, is an investigational neonatal monitoring kit designed to provide real-time, objective data on infants' physiological and behavioral states. The system includes a wristband sensor, imaging camera, tablet application, and a provider portal, enabling healthcare professionals to deliver personalized care and intervention. Visit website.
Shiva Sharareh
CEO
-
Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment. Visit website.
Christopher Carlton
Chairman, Chief Executive Officer and Co-Founder
Don't take our word for it.
Explore real success stories
Sponsorship opportunities
Elevate your brand and
accelerate growth at the
epicenter of the industry




JW Marriott Grosvenor House London
In Mayfair on Park Lane, this 5-star property offers exceptional accommodation, sweeping views, and elite event space. Its Great Room has welcomed royalty, presidents, actors and musicians for the most exclusive events in London since 1929. Guests enjoy modern luxury, inspired service, and award-winning cuisine at the JW Steakhouse or Afternoon Tea at Park Room.




sessions from previous events, captivating photos, and the latest
alumni news. Dive in today to prepare for your next LSI experience.



